UTHRUTHRHealthcare · Drug Manufacturers - Specialty & Generic

UTHR Stock Forecast: United Therapeutics Corp. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$577
−1.16% on the day

The 15 Wall Street analysts covering United Therapeutics Corp. hold a median 12-month price target of $712 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$25.0B
Ticker Nerd rank
79/ 100
Median analyst target
$712
Analysts covering
15
Revenue$783.3M−1.9% y/y
Operating income$330.8M
Net income$333.0M
Free cash flow$205.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.1%
1M
+8.3%
YTD
+18.5%
1Y
+21.1%
From 52W high
−5.1%
From 52W low
+24.2%
$465
$608
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UTHR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores United Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
79/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
98
Quality
89
Momentum
87
Issuance
83
Revisions
48
Growth
42
Accruals
41
Size
8

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (41): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

UTHR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UTHR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800$900Jan 26Apr 26Jul 26Oct 26UTHRHigh $850Median $712Low $390

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
12 Buy2 Hold1 Sell
Low $390Median $712High $850

The green dot is the last close — the median target sits +23.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
9 Nov 2026HC Wainwright & Co.AssumesBuy$660
5 Nov 2026RBC CapitalMaintainsOutperform$697 → $725
5 Nov 2026TD CowenMaintainsBuy$675 → $700
5 Nov 2026Wells FargoMaintainsOverweight$700 → $703
4 Nov 2026BTIGMaintainsBuy$728 → $768
28 Oct 2026JP MorganMaintainsOverweight—
28 Oct 2026JP MorganMaintainsOverweight$710 → $695
22 Oct 2026RBC CapitalMaintainsOutperform$708 → $697
22 Oct 2026RBC CapitalMaintainsOutperform—
19 Oct 2026Leerink PartnersMaintainsOutperform$685 → $725
19 Oct 2026Leerink PartnersMaintainsOutperform—
8 Oct 2026RBC CapitalMaintainsOutperform$677 → $708
8 Oct 2026RBC CapitalMaintainsOutperform—
7 Oct 2026Morgan StanleyMaintainsEqual-Weight$515 → $566
7 Oct 2026Morgan StanleyMaintainsEqual-Weight—
1 Oct 2026BTIGUpgradeBuy$728
1 Oct 2026BTIGUpgradeBuy—
24 Sept 2026Goldman SachsInitiatesSell—
24 Sept 2026Goldman SachsInitiatesSell$321
6 Aug 2026RBC CapitalMaintainsOutperform$704 → $677

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

UTHR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

UTHR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, United Therapeutics Corp. returned +21.1% against +12.2% for the S&P 500, dividends included.

UTHR vs S&P 500, last 12 monthsTotal return, rebased to 100
95100105110115120125130Jan 26Apr 26Jul 26Oct 26UTHRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UTHR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−5.0%
Analysts raising
1
Analysts cutting
6
Fundamentals

United Therapeutics Corp. (UTHR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.2×

Cheaper than 33% of US stocks

Price / sales
7.9×

Cheaper than 15% of US stocks

Price / book
4.0×

Cheaper than 23% of US stocks

EV / EBITDA
17.1×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
4.1%

Higher than 38% of US stocks

Earnings growth (YoY)
−23.6%

Higher than 19% of US stocks

Gross margin
87.3%

Higher than 95% of US stocks

Operating margin
39.4%

Higher than 93% of US stocks

Net margin
38.6%

Higher than 94% of US stocks

Returns & dividend
Return on equity
19.1%

Higher than 80% of US stocks

Return on assets
10.9%

Higher than 93% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

United Therapeutics Corp. (UTHR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • United Therapeutics Corp. has a market value of $25.0B and an enterprise value of $23.1B.

  • Revenue in the twelve months to 30 June 2026: $3.2B. The latest quarter grew 4.1% year on year.

  • Net income over the same four quarters: $1.3B, a 41.6% net margin.

  • Diluted earnings per share, trailing twelve months: $27.95.

  • Free cash flow in the twelve months to 30 June 2026: $1.1B.

  • United Therapeutics Corp. spent $2.6B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 42.7M.

  • Trailing P/E: 22.2×; forward P/E: 17.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • United Therapeutics Corp. employs 1,400 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

UTHR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
UTHRUnited Therapeutics Corp.$25.0B79
VTRSViatris, Inc.$23.6B100
ZTSZoetis, Inc.$34.5B64
NBIXNeurocrine Biosciences, Inc.$16.5B96
ELANElanco Animal Health, Inc.$12.9B97
ALKSAlkermes Plc$7.5B70
AMRXAmneal Pharmaceuticals, Inc.$7.4B83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own United Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UTHR news & analysis

United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

MarketBeat · 17 Nov 2026positive

United Therapeutics is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis. At the UBS London Healthcare Conference, executives also highlighted strong third-quarter sales and upcoming regulatory and clinical milestones.

Why it matters — The potential TYVASO expansion and pipeline milestones are developments UTHR watchers may follow alongside the company’s reported quarterly sales.

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 16 Nov 2026neutral

Zacks Investment Research says investors considering stocks in the Medical - Drugs sector might consider Shionogi & Co. (SGIOY) or United Therapeutics (UTHR).

Why it matters — The item names UTHR as one of two companies for investors to consider in the Medical - Drugs sector.

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

Business Wire · 9 Nov 2026neutral

United Therapeutics announced that CFO and Treasurer James Edgemond will provide an overview and update during fireside chat sessions at two investor conferences in London: the UBS Global Biopharma Conference on November 16, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026.

Why it matters — The scheduled sessions provide UTHR watchers with opportunities to hear a company overview and update from its CFO and Treasurer.

FAQ

Frequently asked questions about UTHR stock

What is the UTHR stock price forecast for 2026-2027?

The 15 Wall Street analysts covering United Therapeutics Corp. have a median 12-month price target of $712, with estimates ranging from $390 to $850. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is UTHR stock a buy right now?

Of the 15 analysts covering United Therapeutics Corp., 12 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks United Therapeutics Corp. 79 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank UTHR?

As at 17 Nov 2026, United Therapeutics Corp. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will UTHR stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks United Therapeutics Corp. 79 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the UTHR stock forecast for 2030?

No analyst covering United Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $390 to $850 over the next 12 months.

How has UTHR stock performed over the past year?

United Therapeutics Corp. returned +21.1% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does United Therapeutics Corp. do?

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease.

What is the latest news on UTHR?

The most recent item we track (Seeking Alpha, 17 Nov 2026): "United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript". United Therapeutics Corporation presented at the Jefferies Global Healthcare Conference 2026, according to a transcript published by Seeking Alpha.

Company

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease. The company also markets Unituxin, a therapy used in the treatment of high-risk neuroblastoma. United Therapeutics combines pharmaceutical research, manufacturing, regulatory operations, and specialized commercial support to serve patients, healthcare professionals, hospitals, and specialty pharmacies. Its business is centered on rare and serious diseases where ongoing treatment and differentiated delivery methods are important, including inhaled, injectable, and oral formulations. The company also operates in regenerative medicine through technologies and programs related to organ transplantation and the development of organs suitable for clinical use. United Therapeutics Corporation therefore occupies a specialized role in biotechnology, linking innovative drug development with advanced approaches to address critical shortages in transplantable organs.

CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. · 1,400 employees · United States · https://www.unither.com